A Phase 1B/2A, Open-label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Fosciclopirox Alone and In Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Latest Information Update: 15 Feb 2024
At a glance
- Drugs Cytarabine (Primary) ; Fosciclopirox (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors CicloMed
- 18 Dec 2023 According to a Notable labs media release, results data from this study further corroborate and extend four independent PPMP validation trials in collaboration with leading medical centers.
- 18 Dec 2023 Initial safety and efficacy results from this trial, presented in a Notable labs media release.
- 14 Nov 2023 According to a Notable labs media release, Safety and efficacy data from the Phase 2a trial for Fosciclopirox, being co-developed with Ciclomed, in adult patients with relapsed/refractory AML are anticipated before year-end 2023.